Network Meta-analysis of Intermittent Fasting and Cardiometabolic Risk

NCT05309057 | Unknown

• 1 other identifier: DNSG-IF
• Study Type: observational
• Target: 25
• Locations: 1 country
• Sites: 2

Brief Summary

Intermittent fasting is a method of restricting calories over a defined period of time and includes regimens such as whole-day fasting, alternate-day fasting, and time-restricted feeding. There is emerging evidence that intermittent fasting or energy restriction might be more beneficial than continuous energy restriction for some risk factors. The effect of intermittent fasting on risk factors associated with obesity, diabetes, and cardiovascular disease, however, is not clear. The European Association for the Study of Diabetes (EASD) has yet to make any recommendations regarding the role of intermittent fasting in the management of diabetes. To inform the update of the EASD Clinical Practice Guidelines for Nutrition Therapy, tthe Diabetes and Nutrition Study Group (DNSG) of the EASD has commissioned a systematic review and network meta-analysis of randomized controlled trials of the effect of different intermittent fasting strategies on established cardiometabolic risk factors. The findings generated by this proposed knowledge synthesis will shape guide current guidelines and improve health outcomes by educating healthcare providers and patients, and by guiding future research design.

Conditions

Obesity; PreDiabetes; Diabetes; Hypertension; NAFLD; Metabolic Syndrome; Dyslipidemias; Inflammation; Gout; Cardiometabolic Syndrome; Cardiovascular Diseases

Keywords

Intermittent fasting; Continuous energy restriction; Weight loss; Systematic review and meta-analysis; Network metanalysis; Randomized controlled trial; Clinical practice guideline; Adiposity; Glycemic control; Blood pressure; Blood lipids; NAFLD markers; Uric acid; inflammatory markers; Cardiometabolic risk factors

Outcome Measures

Primary Outcomes (1)

• Body weight

  Body weight in kg

  Through study completion, up to 20 years

Secondary Outcomes (19)

• Adiposity - BMI

  Through study completion, up to 20 years

• Adiposity - Waist circumference

  Through study completion, up to 20 years

• Adiposity - Body fat

  Through study completion, up to 20 years

• Glycemic control - HbA1c

  Through study completion, up to 20 years

• Glycemic control - fasting plasma glucose (FPG)

  Through study completion, up to 20 years

Study Arms (1)

Studies with intermittent fasting

Studies with intermittent fasting strategies.

Dietary Supplement: Intermittent Fasting

Interventions

Intermittent Fasting DIETARY_SUPPLEMENT

Methods of intermittent fasting strategies, continuous energy restriction, and ad libitum diet.

Studies with intermittent fasting

Eligibility Criteria

• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adults of all health statuses.

You may qualify if:

• Randomized controlled trials in humans
• Intermittent fasting intervention
• Continuous energy restriction, ad libitum diet, or other intermittent fasting diet as comparators
• Diet duration ≥1 weeks
• Data for at least one prespecified outcome
• Viable outcome data

You may not qualify if:

• Non-human studies
• Observational studies
• Children
• Multi-modal interventions
• Diet duration \< 1 weeks
• No viable outcome data
• Lack of suitable comparator

Sponsors & Collaborators

• University of Toronto: lead

Study Sites (2)

Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital

Toronto, Ontario, M5C 2T2, Canada

Location

Faculty of Medicine

Toronto, Ontario, Canada

Location

Related Publications (1)

• Semnani-Azad Z, Khan TA, Chiavaroli L, Chen V, Bhatt HA, Chen A, Chiang N, Oguntala J, Kabisch S, Lau DC, Wharton S, Sharma AM, Harris L, Leiter LA, Hill JO, Hu FB, Lean ME, Kahleova H, Rahelic D, Salas-Salvado J, Kendall CW, Sievenpiper JL. Intermittent fasting strategies and their effects on body weight and other cardiometabolic risk factors: systematic review and network meta-analysis of randomised clinical trials. BMJ. 2025 Jun 18;389:e082007. doi: 10.1136/bmj-2024-082007.

  PMID: 40533200 DERIVED

MeSH Terms

Conditions

Obesity; Prediabetic State; Diabetes Mellitus; Hypertension; Non-alcoholic Fatty Liver Disease; Metabolic Syndrome; Dyslipidemias; Inflammation; Gout; Cardiovascular Diseases; Intermittent Fasting; Weight Loss

Condition Hierarchy (Ancestors)

Overweight; Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Vascular Diseases; Fatty Liver; Liver Diseases; Digestive System Diseases; Insulin Resistance; Hyperinsulinism; Lipid Metabolism Disorders; Pathologic Processes; Arthritis; Joint Diseases; Musculoskeletal Diseases; Crystal Arthropathies; Rheumatic Diseases; Purine-Pyrimidine Metabolism, Inborn Errors; Metabolism, Inborn Errors; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Fasting; Feeding Behavior; Behavior; Body Weight Changes

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: March 16, 2022
• First Posted: April 4, 2022
• Study Start: November 1, 2020
• Primary Completion: June 1, 2022
• Study Completion: August 1, 2022
• Last Updated: April 4, 2022

Record last verified: 2022-03

Data Sharing

• IPD Sharing: Will not share

Locations

CA (2)